retatrutide peptide trial 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in retatrutide clinical trials weight loss

The observations remain preliminary, and rigorous clinical trials are needed to establish efficacy, optimal dosing, and safety profiles for this potential indication

Self-administering an unlicensed compound based on incomplete data is an extraordinary clinical risk

Shi et al., 2024), collectively exacerbating inflammation mediated by the UDPG/P2Y14R axis

An all-in-one app may request or store more categories of personal information, so privacy review matters more, not less

Firstly, these medications can significantly affect blood glucose levels, particularly in patients with type 2 diabetes who may be taking other glucose-lowering agents